Categories: News

nal von minden GmbH rapid test detects the Delta variant

The Delta variant is continuing to spread. “In order to stop it, we need to make sure that we are not transmitting coronavirus to other people,” explains the Federal Ministry of Health, which advises people to get themselves tested. “It is important that the tests can detect the coronavirus mutation. According to a current study by the medical-technology company from Moers (Germany), the nal von minden GmbH rapid test reliably detects the Delta variant. The NADAL COVID-19 antigen test also comes recommended by the Federal Ministry of Health as a means of stemming the pandemic.

“Our rapid test reliably detects the Delta variant,” says Tobias Roth, a biochemist at nal von minden GmbH who specialises in virology. This is shown by a current study carried out by the medical-technology company from Moers, Germany. “We had viral proteins from the mutated Delta variant sent to us and then carried various series of tests using our own rapid test. The result is clear: the Delta variant is detected.”

“Those who use our rapid test can be sure that it will detect the Delta variant,” says Roland Meißner, CEO at nal von minden GmbH. “As the Delta variant is particularly contagious and very widespread, people need reassurance over the quality of rapid and home-use tests. It was therefore very important to us to closely examine the Delta variant in relation to our coronavirus rapid test.”

For the study, nal von minden GmbH generated different dilution series of the nucleocapsid protein (N protein) of the Delta variant. Tobias Roth explains: “Our rapid test uses the so-called nucleocapsid protein as analyte in order to detect a coronavirus infection. This N-protein is also contained within the Delta variant. It acts as a stable shell surrounding the genetic material (RNA) inside the coronavirus. The NADAL test is then used to examine all concentrations of the dilution series in three identical test series (replicates). We can detect the Delta variant just as reliably as the original strain!” In addition, further studies have shown that other previous mutations (referred to by scientists as “Variants of Concern”) from Great Britain, South Africa and Brazil (B.1.1.7, B.1.351 and P.1) are also easily recognised.

Therefore, the high quality that characterises the NADAL rapid test also extends to the Delta variant. The diagnostic specificity is over 99.9 percent, whilst the diagnostic sensitivity is 97.56 percent. The specificity indicates whether healthy people who get tested are in fact healthy, while the sensitivity indicates whether sick people are to be identified as such.

A swab obtained from the lower nasal passage is all that is required to carry out a NADAL COVID-19 antigen test. Results are available after 15 minutes.

www.nal-vonminden.com

Company information

nal von minden GmbH
nal von minden GmbH, based in Moers, Germany, has been a specialist in the field of medical diagnostics for 38 years. Its portfolio includes rapid tests and laboratory tests for reliable diagnoses in the fields of bacteriology, cardiology, gynaecology, infectious diseases, urology and toxicology. nal von minden GmbH has a total of about 230 employees at 9 European locations. www.nal-vonminden.com

Press contact:
Hellwig PR
Gabriele Hellwig
Garstedter Weg 268
D- 22455 Hamburg
Tel.: +49 40 38 66 24 80
E-Mail: info@hellwig-pr.de
www.hellwig-pr.de

Source: RealWire

Staff

Recent Posts

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

31 minutes ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

31 minutes ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

2 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

Hallmark Adds Senior Executives to Enhance Customer Success and Strategic Partnerships

New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…

3 hours ago